DK1423391T3 - Pyrrolopyrimidiner som midler til inhibering af cysteinproteaser - Google Patents

Pyrrolopyrimidiner som midler til inhibering af cysteinproteaser

Info

Publication number: DK1423391T3
Authority: DK; Denmark
Prior art keywords: pyrrolopyrimidines; agents; cysteine proteases; inhibiting cysteine; inhibiting
Prior art date: 2001-08-30

Application number

DK02797553T

Other languages

Danish (da)

English (en)

Inventor

Claudia Betschart

Kenji Hayakawa

Osamu Irie

Junichi Sakaki

Genji Iwasaki

Rene Lattmann

Martin Missbach

Naoki Teno

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-08-30

Filing date

2002-08-29

Publication date

2006-09-25

2002-08-29 Application filed by Novartis Ag filed Critical Novartis Ag

2006-09-25 Application granted granted Critical

2006-09-25 Publication of DK1423391T3 publication Critical patent/DK1423391T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Oncology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Vascular Medicine (AREA)
Pulmonology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Pain & Pain Management (AREA)
Hematology (AREA)
Transplantation (AREA)
Communicable Diseases (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

DK02797553T 2001-08-30 2002-08-29 Pyrrolopyrimidiner som midler til inhibering af cysteinproteaser DK1423391T3 (da)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GBGB0121033.5A GB0121033D0 (en)	2001-08-30	2001-08-30	Organic compounds

Publications (1)

Publication Number	Publication Date
DK1423391T3 true DK1423391T3 (da)	2006-09-25

Family

ID=9921234

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK02797553T DK1423391T3 (da)	2001-08-30	2002-08-29	Pyrrolopyrimidiner som midler til inhibering af cysteinproteaser

Country Status (29)

Country	Link
US (2)	US7452886B2 (fr)
EP (1)	EP1423391B8 (fr)
JP (1)	JP4629334B2 (fr)
KR (1)	KR100695845B1 (fr)
CN (1)	CN100372849C (fr)
AR (1)	AR036374A1 (fr)
AT (1)	ATE326469T1 (fr)
AU (1)	AU2002333760B2 (fr)
BR (1)	BR0212226A (fr)
CA (1)	CA2458684C (fr)
CY (1)	CY1105573T1 (fr)
DE (1)	DE60211530T2 (fr)
DK (1)	DK1423391T3 (fr)
EC (1)	ECSP044998A (fr)
ES (1)	ES2262888T3 (fr)
GB (1)	GB0121033D0 (fr)
HU (1)	HUP0401301A3 (fr)
IL (3)	IL160367A0 (fr)
MX (1)	MXPA04001935A (fr)
MY (1)	MY157368A (fr)
NO (1)	NO328890B1 (fr)
NZ (1)	NZ531343A (fr)
PE (1)	PE20030418A1 (fr)
PL (1)	PL368280A1 (fr)
PT (1)	PT1423391E (fr)
RU (1)	RU2331644C2 (fr)
TW (1)	TWI297690B (fr)
WO (1)	WO2003020721A1 (fr)
ZA (1)	ZA200401042B (fr)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20030144234A1 (en) *	2001-08-30	2003-07-31	Buxton Francis Paul	Methods for the treatment of chronic pain and compositions therefor
SE0201980D0 (sv) *	2002-06-24	2002-06-24	Astrazeneca Ab	Novel compounds
GB0220187D0 (en) *	2002-08-30	2002-10-09	Novartis Ag	Organic compounds
CN1708293A (zh)	2002-09-24	2005-12-14	诺瓦提斯公司	治疗脱髓鞘疾病的鞘氨醇－1－磷酸受体激动剂
AR043692A1 (es) *	2003-02-06	2005-08-10	Novartis Ag	2-cianopirrolopirimidinas y sus usos farmaceuticos
GB0304640D0 (en) *	2003-02-28	2003-04-02	Novartis Ag	Organic compounds
US7498323B2 (en)	2003-04-18	2009-03-03	Ono Pharmaceuticals Co., Ltd.	Spiro-piperidine compounds and medicinal use thereof
AU2004233582B2 (en) *	2003-04-28	2008-05-15	Novartis Ag	Pharmaceutical compositon comprising a cathepsin S inhibitor and an opioid
EP1797883A3 (fr) *	2003-04-28	2007-08-01	Novartis AG	Composition pharmaceutique comprenant un inhibiteur de la cathepsine S et un opiode
BRPI0409685A (pt) *	2003-04-30	2006-04-18	Fmc Corp	derivados cìclicos fenil-substituìdos
WO2005011703A1 (fr) *	2003-08-04	2005-02-10	Akzo Nobel N.V.	Derives 2-cyano-1,3,5-triazine-4,6-diamines
CA2579609A1 (fr)	2003-09-10	2005-03-17	Virochem Pharma Inc.	Composes de spirohydantoine et procedes de modulation de l'activite des recepteurs de chimiokine
JP5084269B2 (ja)	2004-02-18	2012-11-28	アストラゼネカアクチボラグ	テトラゾール化合物及び代謝共役型グルタミン酸受容体アンタゴニストとしてのそれらの使用
US20070197510A1 (en) *	2004-03-10	2007-08-23	Kazuyuki Ohmoto	Nitriles and medicinal compositions containing the same as the active ingredient
ES2251292B1 (es) *	2004-04-20	2007-07-01	Inke, S.A.	Procedimiento para la obtencion de un compuesto farmaceuticamente activo y de sus intermedios de sintesis.
AU2005243238B2 (en) *	2004-05-03	2011-11-10	Janssen Pharmaceutica N.V.	Novel indole derivatives as selective androgen receptor modulators (SARMS)
TW200614993A (en)	2004-06-11	2006-05-16	Akzo Nobel Nv	4-phenyl-pyrimidine-2-carbonitrile derivatives
US7951816B2 (en)	2004-08-27	2011-05-31	Ono Pharmaceutical Co., Ltd.	Compound containing basic group and use thereof
KR100651849B1 (ko) *	2005-02-01	2006-12-01	엘지전자 주식회사	세탁기
CA2617725C (fr) *	2005-08-05	2012-04-03	Hybrigenics Sa	Nouveaux inhibiteurs des proteases a cysteine et leurs applications therapeutiques
WO2007025991A2 (fr)	2005-09-01	2007-03-08	Ares Trading S.A.	Traitement de la nevrite optique
US7326715B2 (en)	2005-09-23	2008-02-05	N.V. Organon	4-Phenyl-6-substituted-pyrimidine-2-carbonitrile derivatives
TW200745055A (en) *	2005-09-23	2007-12-16	Organon Nv	4-Phenyl-6-substituted-pyrimidine-2-carbonitrile derivatives
PE20070530A1 (es) *	2005-10-26	2007-05-31	Smithkline Beecham Corp	Compuestos derivados de tiazoles sustituidos como agentes de apertura de canales de potasio activados por calcio de alta conductancia
PL1961744T3 (pl)	2005-11-18	2013-09-30	Ono Pharmaceutical Co	Związek zawierający grupę zasadową oraz jego zastosowanie
TW200804382A (en) *	2005-12-05	2008-01-16	Incyte Corp	Lactam compounds and methods of using the same
US7687515B2 (en)	2006-01-17	2010-03-30	N.V. Organon	6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives
EP2042503B1 (fr)	2006-05-16	2013-01-30	Ono Pharmaceutical Co., Ltd.	Composé ayant un groupe acide qui peut être protégé et utilisation dudit composé
CN101511802A (zh)	2006-09-13	2009-08-19	阿斯利康(瑞典)有限公司	螺唑烷酮化合物及其作为代谢型谷氨酸受体增效剂的用途
TW200911803A (en) *	2007-07-16	2009-03-16	Organon Nv	6-phenyl-1H-imidazo [4,5-c] pyridine-4-carbonitrile derivatives
US7932251B2 (en)	2007-07-16	2011-04-26	N.V. Organon	6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives
JP2011500673A (ja)	2007-10-19	2011-01-06	アストラゼネカ・アクチエボラーグ	代謝調節型グルタミン酸受容体（ｍｇｌｕｒｓ）の調節因子としてのテトラゾール誘導体
WO2009155475A1 (fr)	2008-06-20	2009-12-23	Novartis Ag	Compositions pédiatriques pour le traitement de la sclérose en plaques
TW201035094A (en)	2009-01-16	2010-10-01	Organon Nv	6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives
US8026236B2 (en)	2009-01-16	2011-09-27	N.V. Organon	6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives
HRP20140754T2 (hr)	2009-06-29	2015-07-17	Incyte Corporation	Pirimidinoni kao inhibitori pi3k
US8759359B2 (en)	2009-12-18	2014-06-24	Incyte Corporation	Substituted heteroaryl fused derivatives as PI3K inhibitors
WO2011082273A2 (fr)	2009-12-30	2011-07-07	Arqule, Inc.	Composés de pyrroloaminopyrimidine substitués
US9115126B2 (en)	2010-01-15	2015-08-25	Merck Sharp & Dohme B.V.	1H-[1,2,3]triazolo[4,5-c]pyridine-4-carbonitrile derivatives
WO2011130342A1 (fr)	2010-04-14	2011-10-20	Incyte Corporation	Dérivés condensés en tant qu'inhibiteurs de ρi3κδ
US9062055B2 (en)	2010-06-21	2015-06-23	Incyte Corporation	Fused pyrrole derivatives as PI3K inhibitors
WO2012027495A1 (fr)	2010-08-27	2012-03-01	University Of The Pacific	Analogues de pipérazinylpyrimidine en tant qu'inhibiteurs de protéine kinase
ES2562274T3 (es)	2010-10-06	2016-03-03	Fundació Institut De Recerca Biomèdica (Irb Barcelona)	Procedimiento para el diagnóstico, pronóstico y tratamiento de metástasis de cáncer de mama
WO2012087881A1 (fr)	2010-12-20	2012-06-28	Incyte Corporation	N-(1-(phényl substitué)éthyl)-9h-purin-6-amines en tant qu'inhibiteurs de pi3k
WO2012125629A1 (fr)	2011-03-14	2012-09-20	Incyte Corporation	Dérivés diamino-pyrimidines et diamino-pyridines substituées en tant qu'inhibiteurs de pi3k
WO2012135009A1 (fr)	2011-03-25	2012-10-04	Incyte Corporation	Dérivés de pyrimidine-4,6-diamine en tant qu'inhibiteurs de pi3k
LT3196202T (lt)	2011-09-02	2019-07-10	Incyte Holdings Corporation	Heterociklilaminai, kaip pi3k slopikliai
AR090548A1 (es)	2012-04-02	2014-11-19	Incyte Corp	Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
EP2650682A1 (fr)	2012-04-09	2013-10-16	Fundació Privada Institut de Recerca Biomèdica	Esters asymétriques d'acides gras utiles en tant que lubrifiants
US9328118B2 (en) *	2012-04-17	2016-05-03	Astellas Pharma Inc.	Nitrogen-containing bicyclic aromatic heterocyclic compound
ES2705237T3 (es)	2012-06-06	2019-03-22	Fundacio Inst De Recerca Biomedica Irb Barcelona	Método para el diagnóstico y el pronóstico de metástasis del cáncer de pulmón
US10119171B2 (en)	2012-10-12	2018-11-06	Inbiomotion S.L.	Method for the diagnosis, prognosis and treatment of prostate cancer metastasis
DK2906718T3 (da)	2012-10-12	2019-07-01	Inbiomotion Sl	Fremgangsmåde til diagnose, prognose og behandling af prostatakræftmetastase under anvendelse af c-maf
AU2014229505B2 (en)	2013-03-15	2020-02-27	Fundacio Institut De Recerca Biomedica (Irb Barcelona)	Method for the prognosis and treatment of cancer metastasis
US20160032399A1 (en)	2013-03-15	2016-02-04	Inbiomotion S.L.	Method for the Prognosis and Treatment of Renal Cell Carcinoma Metastasis
JP6550045B2 (ja)	2013-10-09	2019-07-24	フンダシオ、インスティトゥト、デ、レセルカ、ビオメディカ（イエレベ、バルセロナ）ＦｕｎｄａｃｉｏＩｎｓｔｉｔｕｔＤｅＲｅｃｅｒｃａＢｉｏｍｅｄｉｃａ（ＩｒｂＢａｒｃｅｌｏｎａ）	乳がんに由来する骨の転移がんの予後診断および処置のための方法
US10077277B2 (en)	2014-06-11	2018-09-18	Incyte Corporation	Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors
JP2017538412A (ja)	2014-12-11	2017-12-28	インバイオモーションエセ．エレ．	ヒトｃ−ｍａｆに対する結合メンバー
CN117736209A (zh)	2015-02-27	2024-03-22	因赛特控股公司	Pi3k抑制剂的盐及其制备方法
US9732097B2 (en)	2015-05-11	2017-08-15	Incyte Corporation	Process for the synthesis of a phosphoinositide 3-kinase inhibitor
WO2016183063A1 (fr)	2015-05-11	2016-11-17	Incyte Corporation	Formes cristallines d'un inhibiteur de pi3k
CN117230193A (zh)	2016-05-25	2023-12-15	生物运动有限公司	基于c-maf状态的乳腺癌治疗性治疗
EP3713581A1 (fr)	2017-11-22	2020-09-30	Inbiomotion S.L.	Traitement thérapeutique du cancer du sein basé sur le c-maf
KR102054910B1 (ko) *	2017-12-19	2019-12-12	한림제약(주)	피롤로[2,3-d]피리미딘 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
WO2019204354A1 (fr)	2018-04-16	2019-10-24	C4 Therapeutics, Inc.	Composés spirocycliques
EP3556760A1 (fr) *	2018-04-19	2019-10-23	F. Hoffmann-La Roche AG	Spirocomposés
PE20211208A1 (es)	2018-06-01	2021-07-05	Incyte Corp	Regimen de dosificacion para el tratamiento de trastornos relacionados con pi3k
WO2020201572A1 (fr)	2019-04-05	2020-10-08	Université De Bretagne Occidentale	Inhibiteurs du récepteur 2 activé par une protéase pour le traitement d'une neuropathie sensorielle induite par une intoxication neurotoxique marine
WO2022226166A1 (fr) *	2021-04-22	2022-10-27	Protego Biopharma, Inc.	Imidazolidinediones et imidazolidinones spirocycliques pour le traitement d'une amylose à chaîne légère
WO2023101048A1 (fr) *	2021-12-01	2023-06-08	에스티팜 주식회사	Procédé de préparation d'un dérivé de triazolopyrimidinone

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BE609808A (fr) *	1960-11-02
CH627919A5 (de)	1977-04-14	1982-02-15	Ciba Geigy Ag	Herbizide mittel.
US5958930A (en) *	1991-04-08	1999-09-28	Duquesne University Of The Holy Ghost	Pyrrolo pyrimidine and furo pyrimidine derivatives
DK0682027T3 (da) *	1994-05-03	1998-05-04	Ciba Geigy Ag	Pyrrolopyrimidinderivater med antiproliferativ virkning
US5683999A (en) *	1995-03-17	1997-11-04	The Dupont Merck Pharmaceutical Company	Cyclic urea HIV protease inhibitors
JP3290666B2 (ja) *	1995-06-07	2002-06-10	ファイザー・インコーポレーテッド	複素環式の縮合環ピリミジン誘導体
CA2283961A1 (fr) *	1997-03-19	1998-09-24	Basf Aktiengesellschaft	Pyrrolo [2,3] pyrimidines et leur utilisation comme inhibiteurs de la tyrosine kinase
ATE347362T1 (de) *	1998-06-30	2006-12-15	Lilly Co Eli	Bicyclische spla 2-inhibitoren
JP2002526500A (ja) *	1998-09-18	2002-08-20	ビーエーエスエフアクチェンゲゼルシャフト	プロテインキナーゼ阻害剤としてのピロロピリミジン
CZ303875B6 (cs) *	1999-12-10	2013-06-05	Pfizer Products Inc.	Pyrrolo[2,3-d]pyrimidinová sloucenina a farmaceutická kompozice s jejím obsahem
CA2402516A1 (fr) *	2000-03-20	2001-09-27	Roopa Rai	Inhibiteurs de la protease exempte d'amidine
AU2001241142B2 (en)	2000-04-28	2005-09-22	Tanabe Seiyaku Co., Ltd.	Cyclic compounds

2001
- 2001-08-30 GB GBGB0121033.5A patent/GB0121033D0/en not_active Ceased
2002
- 2002-08-27 MY MYPI20023181A patent/MY157368A/en unknown
- 2002-08-28 AR ARP020103229A patent/AR036374A1/es unknown
- 2002-08-28 TW TW091119570A patent/TWI297690B/zh not_active IP Right Cessation
- 2002-08-29 IL IL16036702A patent/IL160367A0/xx unknown
- 2002-08-29 BR BR0212226-0A patent/BR0212226A/pt not_active Application Discontinuation
- 2002-08-29 PT PT02797553T patent/PT1423391E/pt unknown
- 2002-08-29 DK DK02797553T patent/DK1423391T3/da active
- 2002-08-29 HU HU0401301A patent/HUP0401301A3/hu unknown
- 2002-08-29 PE PE2002000833A patent/PE20030418A1/es not_active Application Discontinuation
- 2002-08-29 US US10/487,760 patent/US7452886B2/en not_active Expired - Fee Related
- 2002-08-29 CA CA002458684A patent/CA2458684C/fr not_active Expired - Fee Related
- 2002-08-29 NZ NZ531343A patent/NZ531343A/en not_active IP Right Cessation
- 2002-08-29 PL PL02368280A patent/PL368280A1/xx not_active Application Discontinuation
- 2002-08-29 AT AT02797553T patent/ATE326469T1/de active
- 2002-08-29 JP JP2003524991A patent/JP4629334B2/ja not_active Expired - Fee Related
- 2002-08-29 AU AU2002333760A patent/AU2002333760B2/en not_active Ceased
- 2002-08-29 ES ES02797553T patent/ES2262888T3/es not_active Expired - Lifetime
- 2002-08-29 RU RU2004109815/04A patent/RU2331644C2/ru not_active IP Right Cessation
- 2002-08-29 CN CNB028168402A patent/CN100372849C/zh not_active Expired - Fee Related
- 2002-08-29 MX MXPA04001935A patent/MXPA04001935A/es active IP Right Grant
- 2002-08-29 EP EP02797553A patent/EP1423391B8/fr not_active Expired - Lifetime
- 2002-08-29 DE DE60211530T patent/DE60211530T2/de not_active Expired - Lifetime
- 2002-08-29 KR KR1020047003048A patent/KR100695845B1/ko not_active Expired - Fee Related
- 2002-08-29 WO PCT/EP2002/009663 patent/WO2003020721A1/fr not_active Ceased
2004
- 2004-02-09 ZA ZA200401042A patent/ZA200401042B/en unknown
- 2004-02-12 IL IL160367A patent/IL160367A/en not_active IP Right Cessation
- 2004-03-01 EC EC2004004998A patent/ECSP044998A/es unknown
- 2004-03-19 NO NO20041180A patent/NO328890B1/no not_active IP Right Cessation
2006
- 2006-08-03 CY CY20061101095T patent/CY1105573T1/el unknown
2008
- 2008-09-25 US US12/237,896 patent/US20090054467A1/en not_active Abandoned
2009
- 2009-05-07 IL IL198643A patent/IL198643A/en not_active IP Right Cessation

Also Published As

Publication number	Publication date
CN100372849C (zh)	2008-03-05
US7452886B2 (en)	2008-11-18
CA2458684A1 (fr)	2003-03-13
US20090054467A1 (en)	2009-02-26
TWI297690B (en)	2008-06-11
NZ531343A (en)	2006-01-27
PT1423391E (pt)	2006-09-29
NO20041180L (no)	2004-03-19
CA2458684C (fr)	2009-04-07
ZA200401042B (en)	2004-10-25
RU2331644C2 (ru)	2008-08-20
GB0121033D0 (en)	2001-10-24
ATE326469T1 (de)	2006-06-15
JP4629334B2 (ja)	2011-02-09
ECSP044998A (es)	2004-04-28
CN1549817A (zh)	2004-11-24
HK1072254A1 (zh)	2005-08-19
EP1423391A1 (fr)	2004-06-02
BR0212226A (pt)	2004-08-17
CY1105573T1 (el)	2010-07-28
IL160367A (en)	2009-12-24
KR100695845B1 (ko)	2007-03-20
EP1423391B1 (fr)	2006-05-17
US20050054851A1 (en)	2005-03-10
EP1423391B8 (fr)	2007-12-12
DE60211530D1 (de)	2006-06-22
HUP0401301A2 (hu)	2004-10-28
AU2002333760B2 (en)	2007-01-04
IL160367A0 (en)	2004-07-25
HUP0401301A3 (en)	2008-03-28
RU2004109815A (ru)	2005-10-20
JP2005502683A (ja)	2005-01-27
MXPA04001935A (es)	2004-06-15
IL198643A (en)	2010-12-30
NO328890B1 (no)	2010-06-07
WO2003020721A1 (fr)	2003-03-13
ES2262888T3 (es)	2006-12-01
KR20040029123A (ko)	2004-04-03
PL368280A1 (en)	2005-03-21
DE60211530T2 (de)	2006-12-21
MY157368A (en)	2016-06-15
PE20030418A1 (es)	2003-06-12
AR036374A1 (es)	2004-09-01

Publication	Publication Date	Title
DK1423391T3 (da)	2006-09-25	Pyrrolopyrimidiner som midler til inhibering af cysteinproteaser
DK1351958T3 (da)	2004-09-06	Imidazol-5-yl-2-anilinopyrimidiner som midler til inhibering af celleproliferation
DK1372737T3 (da)	2006-11-27	Præparat til restenoseprofylakse
NO20041887L (no)	2004-05-07	Benzomidazoler anvendelige som proteinkinase-inhibitorer
NO20033593D0 (no)	2003-08-13	Kinazoliner som MMP-13 inhibitorer
NO20035775L (no)	2004-02-23	3-fluor-pyrrolidiner som anti-diabetesmidler
DE60234125D1 (de)	2009-12-03	E inhibitoren
NO20042955L (no)	2004-07-12	Substituerte fenylaftalener som estrogene midler
DE60237865D1 (de)	2010-11-18	Wippschalter
PT1370553E (pt)	2006-09-29	Inibidores de rhoquinase
NO20033618D0 (no)	2003-08-14	Ftalayinon-piperidino-derivater som PDE-4-inhibitorer
DE60206317D1 (de)	2005-11-03	Umschaltventil
NO20035728L (no)	2004-02-23	Pyrrolopyrimidiner som proteinkinaseinhibitorer
DK1458447T3 (da)	2010-01-18	Kombination af cytokrom-p450-beroende proteasinhibitorer
DK1347739T3 (da)	2006-12-18	Tokomponent-tandplejemiddel til reduktion af mundlugte
DE50201549D1 (de)	2004-12-23	Rückflussverhinderer
DE60202320D1 (de)	2005-01-27	Fluorelastomerzusammensetzungen
DE50207798D1 (de)	2006-09-21	Tensidmischungen
DK1429607T3 (da)	2007-08-13	Delta-1-pyrroliner som pesticider
DE60201627D1 (de)	2004-11-25	Fluorelastomerzusammensetzungen
DE60214239D1 (de)	2006-10-05	Schwinghebel
ATE429431T1 (de)	2009-05-15	2-amino-benzoxazol-suphonamide als breitspektrum- hiv-protease-inhibitoren
NO20033234L (no)	2003-09-22	Karotenoider som antihypertensjonsmidler
ITTO20020789A1 (it)	2003-03-14	Formulazione solida
DE50204477D1 (de)	2005-11-10	Schieberventil